Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
64.06 ^USD	+2.23%		+3.12%	-16.98%

Apr. 26	Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay	CI
Apr. 23	Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe	MT

Bio-Techne Corporation Appoints Kim Kelderman as Chief Executive Officer Effective February 1, 2024

January 05, 2024 at 07:00 am EST

Bio-Techne Corporation announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024.

Latest news about Bio-Techne Corporation

Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay	Apr. 26	CI
Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe	Apr. 23	MT
Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85	Apr. 18	MT
RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating	Apr. 08	MT
Bio-Techne Positioned for Growth Amid Biotech Funding Recovery, UBS Says	Mar. 28	MT
Bio-Techne Says European Union IVDR Certification Received for Diagnostic Test Tracking Chronic Myeloid Leukemia	Mar. 22	MT
Transcript : Bio-Techne Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 09:45 AM	Mar. 19
Transcript : Bio-Techne Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM	Mar. 13
North American Morning Briefing : Hopes of March -2-	Feb. 05	DJ
Stephens Adjusts Bio-Techne's Price Target to $87 From $70, Keeps Overweight Rating	Feb. 02	MT
Deutsche Bank Cuts Bio-Techne Price Target to $85 From $88, Maintains Buy Rating	Feb. 02	MT
RBC Cuts Price Target on Bio-Techne to $75 From $85, Notes Revenue Growth Turned Negative, Keeps Sector Perform Rating	Feb. 02	MT
Stifel Nicolaus Downgrades Bio-Techne to Hold from Buy, $65 Price Target	Feb. 02	MT
Bio-Techne Seeks M&A	Feb. 01	CI
Transcript : Bio-Techne Corporation, Q2 2024 Earnings Call, Feb 01, 2024	Feb. 01
Bio-Techne's Fiscal Q2 Adjusted Earnings Fall, Net Sales Rise	Feb. 01	MT
Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q2 Revenue $272.6M, vs. Street Est of $277.7M	Feb. 01	MT
Bio-Techne Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 01	CI
Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended December 31, 2023, Payable February 26, 2024	Feb. 01	CI
North American Morning Briefing : Stock Futures -2-	Feb. 01	DJ
Bio-Techne Corporation Sets New Standard with the Development of A Next-Generation, Protease-Free RNAscope Spatial Multiomics Workflow	Jan. 29	CI
Transcript : Bio-Techne Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM	Jan. 10
Bio-Techne Corporation Appoints Kim Kelderman as Chief Executive Officer Effective February 1, 2024	Jan. 05	CI
Bio-Techne Corporation Appoints Matthew F. Mcmanus as President, Diagnostics and Genomics Segment, Effective January 8, 2024	Jan. 05	CI
Bio-Techne Files Drug Master File With US FDA for ExCellerate GMP for Stem Cell Therapy	Dec. 20	MT

Chart Bio-Techne Corporation

Duration

Period

More charts

Company Profile

Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q3 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Bio-Techne Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

64.06 USD

Average target price

80.43 USD

Spread / Average Target

+25.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIO-TECHNE CORPORATION	-16.98%	10.07B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research